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Transcription Mediated Amplification for 
the Diagnosis of HCV RNA
What is TMA?
How TMA Detects HCV RNA?
Detection of Amplified Products
Ms Saima Javed, 
Technologist, Molecular Pathology
TMA, Transcription Mediated amplification is an 
isothermal (single temperature), autocatalytic (self 
starting) nucleic acid target amplification system that 
can produce more than a billion RNA copies of target 
DNA or RNA in an hour or less.                                                           
TMA can detect HCV RNA in human plasma and 
serum.  It has three main steps which are Sample 
preparation, target amplification and amplicon 
detection. Sample preparation involves detergent 
lysis of virus followed by hybridization of free viral 
nucleic acid probes oligonucleotide complimentary 
to the 5' untranslated region (conserved region) of 
HCV genome.  An internal control is hybridized in the 
same manner.  The hybridized targets are then 
captured on to magnetic particles which firmly hold 
captured targets and allow thorough washing to 
remove potential inhibitory substances.
  
TMA starts with the addition of primers, nucleotides, 
reverse transcriptase (RT) and RNA polymerase (RP). 
Figure 1 depicts TMA cycle.
Identification of amplicons is accomplished by 
hybridization protection assay (HPA) and dual kinetic 
assay (DKA) as explained in figure 2. In HPA single 
stranded DNA probes are labelled with two different 
chemiluminescent acridinium ester (AE) molecules. 
One is specific for internal control RNA(IC RNA) 
and another is specific for HCV amplicon. AE 
molecules are chemically modified and have different 
kinetics for duration of light emission. AE molecules 
labelled probes bind specifically with amplicons and 
are protected from hydrolysis while non-specifically 
bound and unbound AE molecules are hydrolyzed 
after addition of selection reagent and then auto detect 
reagent is added which causes the protected AE 
molecu les  on  annea led  p robes  to  emi t  
chemiluminescent signals. The dual kinetic nature of 
these AE molecules results in shorter “flasher signal” 
and longer “glower signal”. Light emission is 
measured and expressed numerically in relative light 
units (RLUs).  Results are reported by TMA data 
reduction software.
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Primer1
  Reversetranscriptase
RT creates cDNA 
from it.
RNA:DNA duplex is 
completed.
RNAse H activity of 
RT degrades the 
target RNA.
Primer 2 binds to 
this cDNA.
Double stranded 
DNA is generated by 
RT.
Primer 1 binds to target 
RNA. 
Double stranded DNA template
RNA polymerase initiates 
transcription of RNA from dsDNA
template
Production of 100-1000 
copies of RNA amplicon
Primer 2 binds to RNA 
amplicon and creates 
cDNA
Primer 1 binds to cDNA and 
creates dsDNA
RNAse-H activity 
of RT degrades 
RNA amplicon
RNA:DNA duplex 
is completed
Figure1:  
Steps Involved  in Transcription Mediated Amplification
AE labelled probes
RNA amplicon
AE probe binds specifically to RNA 
amplicon 
Unhybridised probe is hydrolyzed
Probe set 1 (Internal control)
Probe set 2 (Analyte)
Signal 1 “Flasher” for IC RNA
Signal 2 “Glower” for Analyte (HCV)
Figure 2:  
Schematic Diagram of HPA and DKA
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Result Interpretation
 Advantages of TMA
Why TMA is Preferred Over PCR Based Assay? 
Conclusion
TMA Data Reduction Software calculates two cut 
offs. Analyte cut off for Analyte signal and IC cut off 
for IC signal.  Sample is considered negative when 
analyte signal is less than the Analyte cut off 
(i.e.Analyte S/CO‹1) and an IC signal is greater than 
or equal to IC cut off. Sample result is considered 
positive when Analyte signal is greater than or equal 
to Analyte cut off (i.e. Analyte S/CO=1) and IC signal 
is less than or equal to 475,000 RLUs. 
It is a single tube assay with few steps, which 
makes it fast. 
TMA produces RNA amplicons which are 
unstable in lab environment and are easily 
inactivated by deactivation fluid.
HPA reaction eliminates washing steps which 
minimise the risk of carry over contamination.  
TMA Does Not Require Special Equipments:
TMA is isothermal; a water bath or heat block is 
used instead of a thermal cycler.
TMA is Rapid: PCR produces two copies per 
cycle whereas TMA produces 100-1000 of RNA 
amplicons per cycle that results in 10 billion fold 
increase within about 15-30 min.
TMA has higher sensitivity: It has potential to 
detect less than 50 HCV RNA copies per ml and 
residual viremia while PCR based assay has 
lower detection limit of 100-1000 HCV RNA 
copies per ml and is not suitable for detecting 
residual viremia in HCV patient.
Amplification by TMA is relatively simple, rapid and 
extremely sensitive when compared with PCR. It is 
FDA approved and provides good clinical 
performance especially when detecting response to 
therapy for viral clearance.  Hence, TMA can be 
incorporated in routine laboratory diagnosis of 
hepatitis C virus.
!
!
!
!
!
!
Vanillyl Mandelic Acid
Introduction
Significance
Collection and Storage
Reference Range
Dr Sahar Iqbal
Resident, Chemical Pathology
 
The catecholamines (Epinephrine and nor-
epinephrine) are secreted from the Adrenal Medulla. 
Most of the catecholamines are metabolised by mono-
amino oxidase and chtechol-o-methyl transferase 
(COMT) and produce major urinary metabolite 
vanillyl mandelic acid (VMA). The others 
metabolites are metanephrin and nor-metanephrin. 
Pheochromocytoma is the catecholamine producing 
tumour of adrenal medulla, which can be diagnosed 
by assessing the urinary level of VMA. In addition, 
neuroblastoma, a common malignant tumour of 
childhood, can also be diagnosed by urinary VMA. 
About 75 per cent of the patients with neuroblastoma 
show increased urinary level of VMA, however in 
healthy children at least up to age of 15 years urinary 
VMA and metanephrin tend to be high and variable 
than adults. 
 
Urinary VMA measurements are commonly used to 
screen for pheochromocytoma. It is more specific but 
less sensitive than metanephrine measurement. It 
helps in early diagnosis of pheochromocytoma, as 
undiagnosed pheochromocytoma is a potentially 
lethal condition. 
 
Patient is instructed to collect a 24 hours urine 
specimen. VMA is stable at room temperature upto 
five days. Hydrochloric acid is used to preserve the 
specimen for longer than five days before analysis.
In adults, reference value for VMA in 24 hours urine 
collected specimen is approximately 7.0 mg (range 
1.9 - 9.8 mg/24 hour). False positive results (more 
than reference range) may be seen in the patients 
taking salicylate, caffeine, phenothiazines and 
antihypertensive agents. Coffee, tea, chocolate, fruit 
(bananas) and vanilla containing substances should 
be avoided for 72 hours prior to collection. 
3
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blue, calcofluor, Giemsa, toluidine blue, Gomori 
methenamine silver, immunofluorescent and Gram-
Weigert. All these methods are highly efficient in the 
hands of experienced microscopists. 
One of the most widely used methods is 
immunofluorescence using direct fluorescein 
conjugated monoclonal anti Pneumocystis antibodies 
which stains and fluoresces the walls of the trophic 
forms and cysts, apple green. This technique is 
available at the Department of Microbiology, AKUH.
Serological assays detecting Pneumocystis 
antibodies and antigens have not been clinically 
useful. PCR based methods, although more sensitive 
are costly, labour intensive and are not widely 
available.
Pneumocystosis should be considered in any 
immunocompromised patient presenting with fever, 
respiratory symptoms and an abnormal chest 
radiograph. Current microscopy based methods have 
produced results concordant with clinical diagnosis. 
They therefore remain as a mainstay for diagnosis.
Stain : immunofluorescence test (IFA)
Magnification:  x 400 
Round to oval shaped cysts and extracellular matrix 
seen.
Trophozoites and sporozoites may be embedded in 
extracellular matrix and fluoresce apple green.
Other Diagnostic Modalities
Conclusion
Diagnosis of Pneumocystis jiroveci 
Infections in Microbiology Laboratory
Introduction
Diagnosis
Stains
Dr Summiya Nizamuddin
Resident, Microbiology
Pneumocystis jiroveci previously known as 
Pneumocystis carinii is one of the most common 
opportunistic pathogens in HIV infected patients. 
Currently it is classified as a fungus, with a tropism 
for growth on respiratory surfaces leading to 
pneumonia. The organism is found in three distinct 
morphological stages. The trophozoite or trophic 
form, the sporozoite, and cyst, which contains 
intracystic bodies also known as spores.
P jiroveci cannot be propagated continuously in host 
cell free culture systems. Hence, its diagnosis at 
present is dependent on the morphological 
identification of the organisms on microscopy. 
Various respiratory specimens (sputum, induced 
sputum, tracheal aspirate fluid, bronchoalveolar 
lavage (BAL) fluid, tissue obtained by transbronchial 
biopsy, cellular material obtained by bronchial brush, 
pleural fluid, and tissue obtained by open thorax lung 
biopsy) could be sent to laboratory for detection.
The diagnostic yield of the various specimens is 
critically dependent on the underlying diseases of the 
patient, the expertise of the staff evaluating the patient 
and obtaining the specimen, and the expertise of the 
laboratory staff for processing and examining the 
specimen. Generally, the more invasive the 
procedure, the better is the diagnostic yield which 
ranges from 50-90 per cent for induced sputum to >90 
per cent for BAL. Moreover sensitivities are also 
h igher  in  AIDS pat ients  than  in  o ther  
immunocompromised patients owing to the higher 
burden of these organisms. 
By use of rapid processing and staining techniques, a 
laboratory diagnosis of PCP can usually be made 
within a few hours. 
A variety of stains have been used for the 
identification of Pneumocystis. Commonly used 
fungal stains are periodic acid Schiff (PAS), toluidine 
4
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Laboratory Diagnosis of Metabolic Bone 
Diseases
Dr Aysha Habib Khan
Assistant Professor and Consultant Chemical 
Pathologist
The principal differential diagnosis in patients 
presenting with bone fractures, bone pain and reduced 
bone mineral density is osteoporosis versus 
osteomalacia. This distinction is made from the 
history, physical examination and a combination of 
laboratory and radiological studies. 
For an uncomplicated patient with osteomalacia and 
osteoporosis, a lab workup includes serum calcium, 
phosphate, creatinine, magnesium, alkaline 
phosphatase, vitamin D (25OHD) Parathyroid 
hormone (PHT), Thyroid stimulating hormone (TSH) 
and 24-hour urine calcium. Males should have 
testosterone measured. 
The main purpose of laboratory tests is to check for 
abnormalities of calcium/phosphate metabolism and 
secondary causes of osteoporosis such as renal or 
hepatic failure, acidosis and hypercalciuria. 
Secondary causes of osteoporosis often go undetected 
in part because of the lack of specific guidelines for 
laboratory evaluation in newly diagnosed cases.
Measurement of serum total calcium and phosphate 
concentrations, although readily available tests; are of 
limited value in the assessment of osteoporosis. 
However, low concentrations of serum phosphate and 
calcium are indicative of osteomalacia. Alkaline 
phosphatase is an inexpensive method of checking for 
osteoblastic activity. The 24-hour urine calcium 
measurement is frequently ignored but it is a valuable 
and inexpensive test. High levels are seen in 
idiopathic hypercalciuria, and low levels suggest 
malabsorption, vitamin D deficiency, etc. The test 
should be done on a patient's customary calcium 
intake. 
The measurement of vitamin D is becoming 
increasingly important in the management of patients 
with various disorders of calcium metabolism 
associated with rickets and osteomalacia, neonatal 
hypocalcaemia, pregnancy, nutritional and renal 
os teodyst rophy,  hypopara thyroidism and 
hyperparathyroidism and osteoporosis.
Mild vitamin D deficiency frequently occurs in the 
absence of hypocalcaemia, especially in Asians. 
Secondary hyperparathyroidism may occur with 
normal calcium; most of these cases are detected by 
low calcium, low 25OHD levels or decreased renal 
function. In patients with abnormal serum calcium or 
with unusually severe bone disease, the 25-OH D and 
PTH levels should always be measured. The 25 OH D 
provides more useful information than the 1, 25   
(OH)  vitamin D level.
2
Protein electrophoresis should be done whenever a 
patient presents with new fractures. Corticosteroid 
excess that causes osteoporosis can usually be 
detected clinically by cushingoid features. A urine 
cortisol can be helpful in puzzling cases. 
Gonadal hormones are very important causes of 
osteoporosis. In females who are postmenopausal, it 
is not helpful to measure levels of estrogens or 
gonadotropins. In males, however, testosterone levels 
should be measured because there is much greater 
variability in the prevalence of hypogonadism. Also, 
men may have low testosterone without other clinical 
symptoms. If testosterone is low, then further work-
up is needed.
In conditions where renal wasting of phosphate is in 
question, then measurement of urinary phosphate 
excretion should be helpful. Phosphate excretion is 
measured by calculation of the fractional excretion of 
filtered phosphate from a random urine specimen by 
measuring serum and urinary phosphate and serum 
and urinary creatinine. 
To conclude, laboratory testing plays an important 
role in the early diagnosis and management of 
metabolic bone diseases. It is important that 
appropriate investigations are requested after 
establishing a differential diagnosis. The relation of 
the lab results to the disease may be complex. At 
times, a close liaison between laboratory and 
physician provides a better judgment.
5
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24 Hours Urinary Specimen Collection
Types of Urine Collection
Methods for Preserving Urine Samples
Dr Ayaz Baig
Resident, Chemical Pathology
The urine specimen has been referred to as a liquid 
tissue biopsy of the urinary tract that is painlessly and 
easily obtained. Urine yields a great amount of 
valuable information quickly and economically, but 
as for all other human specimens used in laboratory, 
the urine must be carefully collected, preserved, and 
processed for the information to be regarded as 
reliable.
1. Random: these specimens usually do not require 
any preservative
2. Timed specimen: usually 24 hour sample is 
preferred for most of these specimens and this 
requires a suitable preservative
Various methods of preserving urine are available, 
most of which inhibit the growth of bacteria, thus 
preventing many alterations from occurring. The best 
method is immediate refrigeration during and after 
collection. The specimen may be kept 6 to 8 hours 
under refrigeration with no gross alterations and 
without any preservative. There are several chemicals 
available for preservation.
Toluene is one chemical preservative which is in 
liquid form and inhibits growth of bacteria. It forms a 
thin layer which covers surface of urine. It is the best 
preservative as it does not interfere with various tests 
done in routine urinalysis.
Thymol, a crystalline substance, inhibits the growth 
of bacteria but it may interfere with protein and 
bilirubin estimation.
Formalin, a liquid preservative acts by fixing the 
formed elements in urine sediment, however it 
interferes with reduction tests for urine sugars and 
may form precipitate with urea that interfere with 
microscopic examination of sediment.
Boric acid is used to preserve creatinine, uric acid and 
proteins
Hydrochloric acid is used to preserve calcium, 
phosphate and oxalate 
When a 24 hour sample is sent to the laboratory it 
should be ascertained that it has been properly 
collected. A preservative has been added at the 
beginning of collection and the correct collection time 
is used.
The patient is carefully instructed about details of 
collection process. The bladder is emptied at the start 
of collection (e.g. in the morning at 8:00 AM) and this 
time is noted on collection container. This urine is 
discarded and not put into container. All subsequent 
voiding are collected and put into container up to and 
including urine at 8 AM the following morning. This 
urine specimen will complete the 24 hours collection.
At Clinical Laboratories and all its collection centres, 
patient information regarding collection of urine is 
available. In addition, bottles for 24 hour urine 
collection are also available at the receptions. These 
bottles do not contain any preservative.
Instructions for the Patients
At AKUH Clinical Laboratories 
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Genetic Analysis of Duchenne Muscular 
Dystrophy
What is Dystrophy?
 
Ms Asma Hanif
Assistant Technologist, Molecular Pathology
Duchenne Muscular Dystrophy (DMD) was first 
described in 1986 by Guillaume Benjamin Amand 
Duchenne.
Dystrophy is basically a group of disorders that affect 
body muscles. DMD occurs when a particular gene on 
X chromosome fails to encode correct message for a 
protein known as dystrophin. The gene is located on 
Xp21 and has 79 exons spanning 2.5 megabases. It 
produces mRNA of 14.6 kilobases and a protein of 
over 3500 amino acid residues. Dystrophin connects 
cytoskeleton of muscle fibers to the surrounding 
extracellular matrix through the cell membrane. 
Dystrophin associated muscular dystrophies range 
from milder Becker muscular dystrophy to severe 
DMD. Almost 70 per cent of the cases occur because 
of inheriting a defective gene while 30  per cent result 
from new mutations. Although the majority of 
deletion mutations are found at 3' end, the point 
mutation can occur along entire gene. Point mutations 
create stop codons that produce severely reduced or 
absent levels of dystrophin which links actin filaments 
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7to a complex of transmembrane proteins and hence to 
the extracellular matrix (Figure 1).
The symptoms of the disease become apparent 
between three to five years of age resulting in 
enlargement of calf muscles, weakness of arm that 
progressively loses strength in shoulders. In DMD, 
creatine kinase leaks out of the muscle fibres and is 
therefore found in greatly increased amounts in the 
serum. In young boys with DMD, the serum 
creatinine kinase level is at least five times as high as 
the maximum for unaffected people and sometimes it 
is 50 to 100 times as high. As the disease progresses, 
failure of heart muscles and malfunction of organ 
systems ultimately leads to death.
Male offspring have a 50:50 chance of inheriting the 
affected chromosome and thereby developing DMD 
as it is an X-linked recessive disorder (Figure 2). 
Females tend to be mildly affected compared to males 
because females have a second X chromosome to 
compensate for the defective gene.
Symptoms
Inheritance
Diagnosis
Figure 3: 
Results of gel electrophoresis in a patient with DMD
Conclusion
DNA is isolated from peripheral blood leukocytes 
using standard salting out procedure. Polymerase 
chain reaction assay of dystrophin gene is carried out 
using primers specific for various exons and promoter 
region. PCR products are then separated on an 
agarose gel containing ethidium bromide and bands 
are visualised under UV light. Dystrophin gene is 
amplified in 6 sets of PCR reactions. Each set includes 
3-5 exons; details of exons are listed in the following 
table.
MWM 1 2 3 4 5 6
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5 Lane 6
45 48 Pm 3 49 PB
19 17 43 50 16 41
51 8 13 6 32 42
42 44 47 60 34
46 4 52
Figure3: Indicate deletion of exons 45 and 46 in lane 
1, exon 52 in lane 3 and 34 in lane 6 or 5 thus 
confirming the diagnosis of DMD.  
MWM=Molecular Weight Marker 100bp.
Multiplex PCR is a useful assay for the diagnosis of 
deletion in DMD gene, when compared with 
Southern blotting it is more sensitive and rapid. 
Presently, preventive measures or treatment is not 
available for these disorders but molecular techniques 
such as multiplex PCR can be used for their early 
identification and better management. 
Extracellular matrix
Dystrophin-Glycoprotein complex
Linking protein
Actin filamentá-helix
Dystrophin
Actin binding region
Figure: 1
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8Hybrid of Cystic Adenomatoid 
Malformation with Pulmonary Sequestration
Abstract
Introduction
Case Report
Ms Fatima Mubarik, Naila Nadeem, Zishan Haider, 
Gulnaz Shafqat, Shaista Afzal,
Radiology
This is a case report of full term baby boy who was 
antenatally diagnosed of having an echogenic lung 
mass. The neonate under went CT scan and 
consequently thoracotomy and was found to have 
hybrid form of cystic adenomatoid malformation 
(CCAM). The case report reminds us that cystic 
adenomatoid malformation and pulmonary 
sequestration are included in spectrum of 
bronchopulmonary foregut malformation and if we 
detect one pathology we should  look for other 
pathologies as these can coexist.
CCAM and pulmonary sequestration are congenital 
lesions that have distinct embryology, pathology and 
natural history. Seventeen cases of intralobar 
pulmonary sequestration with CCAM and 19 cases of 
extra lobar pulmonary sequestration with CCAM 
have been described since 1949(1).
Patient was a baby boy born through emergency 
lower segment caesarian section due to foetal distress 
at 40th week of gestation. Birth weight of 3.3 kg, 
Apgar score was 8 at 0/min, baby was tachypenic with 
respiratory rate of 80/min and had sub costal 
recession.
Antenatal ultrasound showed echogenic lung mass 
with cystic changes in left chest, it was interpreted as 
adenoid cystic malformation. On postnatal 
examination, child was found to have displaced apex 
beat, chest X-ray revealed air space shadowing with 
cystic changes in left lower lobe with contra lateral 
mediastinal shift. 
 
Enhanced CT chest confirmed X-ray findings. In 
addition, an aberrant vessel from thoracic aorta 
directed toward affected region was visualised. By 
virtue of its position and appearance, diagnosis of 
sequestered lung was suggested. On third postnatal 
day, posteriolateral thoracotomy through 5th 
intercostals space was carried out, intralobar 
pulmonary sequestration was found in left lower lobe 
with aberrant blood supply from descending thoracic 
aorta.
Sample was sent for histopathology. Features were 
consistent with congenital cystic adenomatoid 
malformation type II (multiple small cysts < 1cm in 
diameter). Child recovered well after surgery and was 
discharged. 
 
                                   
 
             
Pulmonary sequestration are  regions of lung 
parenchyma which lack normal connection to 
tracheobronchial tree and possess an anomalous 
systemic blood supply usually from aorta or its major 
branches (2). Its incidence is 0.15per cent -1.7per cent 
in general population. It was first described by 
Rokitansky and Rektorzik in 1861 (1). 
Figure 1:
 Chest X-ray Showing Increased Density with 
Cystic Changes in the Left Lower Lung Zone.
                               
Figure 2:
 CT Scan Chest Lung Parenchyma Producing a Solid Density in the 
Posteromedial Segment of Left Lower Lung
Discussion                                    
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There are two types of sequestration, intralobar and 
extralobar sequestration (3). CCAM is a 
developmental hamartomatous abnormality of lung 
with adenomatoid proliferation of cysts resembling 
bronchioles (4). Chin and Tang first described CCAM 
as a distinct entity in 1949 (5). CCAM represent 
approximately 25 per cent of all congenital lung 
lesions. CCAM communicate with bronchial tree and 
derive their blood supply from pulmonary circulation. 
The review of hybrid lesions by Cass et al suggested 
that prognosis in hybrid CAMS appears to be more 
favourable than CAM without a systemic feeding 
vessel (6).
Intra abdominal extralobar pulmonary sequestration 
/CCAM seem to have a good prognosis. 
Complications such as respiratory distress, infection, 
intrathoracic bleeding, haemoptysis, cardiac failure 
can occur. The potential risk of malignancy 
necessitates surgical excision of this congenital 
pulmonary lesion (7).
Ultrasonic evaluation of lung lesion done antenatally 
with good postnatal imaging algorithm has a strong 
impact on patient management and prognosis in 
pulmonary sequestration /CCAM.
1. Madan Samuel. Management of antenatally 
diagnosed pulmonary sequestration associated 
with pulmonary sequestration associated with 
congenital cystic adenomation malformation. 
Thorax 1999;54:701-706
2. J S C Chen, N walford, Y L Yan. Fetal Intralobar 
lung sequestration: Antenatal diagnosis and 
management. Singapore med J 2003 vol 44(12): 
630-634.
3. Mukhtar Ahmad, Volmar Jacobi, Thomas J Vogl. 
Multislice CT and CT angiography for non-
invasive evaluation of bronchopulmonary 
sequestration. European radiology 2003
4. Caffeys pediatric Xray diagnosis 8th edition
5. Orpen N, Goodman R, Bowker C, Lakhoo K 
Intralobar pulmonary sequestration with 
congenital cystic adematous malformation and 
rhabdomyomatous dysplasia. Pediatr Surg Int. 
2003 Oct;19(8):610-1. Epub 2003 Oct 09.
6. Sakala EP, Perrott WS, Grube GL. Sonographic 
characteristics of antenatally diagnosed extralobar 
pulmonary sequestration and congenital cystic 
adenomatoid malformation. Obstet Gynecol Surv. 
1994 Sep;49(9):647-55
7. Chin KY, Tang MY. Congenital adenomatoid 
malformation of one lobe of a lung with general 
anasarca. Arch Pathol 1949; 48:221-9
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How Can We Achieve Good Response 
From Trans-Arterial Chemo-Embolisation 
(TACE)?
Inclusion Criteria
Exclusion Criteria
Ishtiaq Ahmed Chishty, Zishan Haider, Dawar Khan, 
Tanveer ul Haq, Radiology
Viral hepatitis is becoming common in Pakistan. 
Hepatoma is a lethal sequelae of chronic liver disease. 
Hepatoma is among the leading causes of death 
worldwide as well. The prognosis of hepatoma is grim 
particularly when the tumour is unresectable or when 
orthotropic liver transplantation is contraindicated. 
This tumour receives most (90-100 per cent) of their 
supply from hepatic artery, therefore Transarterial 
Chemoembolisation (TACE) is the most common 
technique used to treat unresectable HCC. TACE can 
reduce viable tumour tissue and improves survival.
Patient selection for TACE is a difficult task, because 
treatment of hepatoma can be influenced by liver 
function, vascular invasion, tumour size and 
vascularity. Clinically, if the patient has massive 
ascites and encephalopathy, the response of TACE is 
poor. Inclusion and exclusion criteria for TACE are 
mentioned below:
Unresectable tumors
Patent portal vein
Satisfactory Liver function (Normal alkaline 
phosphatase and aspartate transaminase level)
Serum bilirubin level < 2mg/dl (34 micromol/l)
No major contraindication to angiography (e.g. 
normal coagulation and renal function)
Clinically apparent jaundice 
Hepatic encephalopathy
Occluded portal vein
Hepatofugal portal vein flow
Extra-hepatic tumours 
Other medical conditions likely to be life 
threatening within three months
Liver rupture or tumour invasion of liver capsule
Poor liver function 
(Coagulopathy is not correctable with Vitamin K, 
Lactate dehydrogenase level >425 IU/L, elevated 
alkaline phosphate level)
Serum bilirubin level > 5mg/dL (85ìmol/l)
!
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Biliary Obstruction 
Serum creatinine > 2mg/dl (177µmol/l)
Haemoglobin Level < 8 g/dl (80 g/l)
3 9 
White blood cell count < 2.5×10 /µl (2.5×10 /l)
3 9 
Platelet count < 60×10 /µl (60×10 /l)
Pregnancy
Liver involvement > 50per cent
Albumin < 35g/L
Aspartate aminotransferase level >100 IU/L
In our institute, we are using Child-Pugh 
classification for the selection of patient for TACE. 
The Child-Pugh Classification system which relies on 
following biochemical and clinical criteria,
a. Bilirubin level 
b. Albumin level
c. Prothrombin time 
d. Degree of Ascites
e. Hepatic encephalopathy
These criteria have been successfully used for many 
years to provide an accurate reflection of patient's 
liver function. We do not perform procedure in Child-
Pugh Class C patients. Table 1 is showing scoring 
system of Child-Pugh Classification.
Table 1: Child-Pugh Classification of Liver Function
         Score 1             2     3
Ascites Absent Slight to moderate Severe
Encephalopathy Absent Slight to moderate Severe
Serum Albumin >3.5 g/dl 2.8-3.8 g/dl <2.8 g/dl
Serum Bilirubin <2 mg/dl 2-3 mg/dl >3 mg/dl
PT* Prolongation <4 second 4-6 second >6 second
*PT=Prothrombin Time
Score of 5-6 corresponds to Child-Pugh Class A
Score of 7-9 corresponds to Child-Pugh Class B
Score of 10-15 corresponds to Child-Pugh Class C
Portal vein occlusion is not an absolute 
contraindication for TACE. To achieve substantial 
tumour necrosis, delaying progression to liver failure, 
chemoembolisation is a well established procedure 
for patients with unresectable hepatoma. TACE is an 
effective way to improve survival and quality of life. 
We can achieve good response from trans-arterial 
chemoembolisation by proper selection of patients 
(Fig 1, 2, 3).
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Figure1: 
Pre-TACE contrast enhanced -CT scan shows enhancing 
hepatoma in segment IV of liver
Figure2: 
Same patient after three sessions of TACE: Contrast enhanced -CT 
scan is showing minimal residual vascularity in treated tumour
Figure3: 
Same patient after three years: There is no appreciable 
tumour vascularity on contrast enhanced CT scan.
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Anti-factor Xa Assay
Natasha Ali, 
Resident, Haematology
Heparin is used widely for the prevention and 
treatment of thromboembolic diseases and is also 
utilised during procedures of haemodialysis and 
cardiopulmonary bypass surgeries. Two types of 
heparin preparations widely in use today are 
unfractionated heparin (UFH) and low molecular 
weight heparin (LMWH). The inconvenience and 
limited precision of monitoring of (UFH)  therapy has 
contributed to the increasing use of LMWH 
preparations. The pharmacokinetic properties of 
LMWH are different from (UFH) and allows for 
easily monitored anticoagulant effects of a given 
dose. Monitoring is, however recommended in the 
following clinical settings like renal insufficiency, 
obesity, paediatric patients and those on prophylactic 
anticoagulant therapy in conditions like malignancy 
or antiphospholipid syndrome. Anti factor Xa assay is 
used to monitor LMWH therapy.
Principle of anti- factor Xa is based on the fact that 
both factor Xa and antithrombin III are added in 
excess amounts to the test plasma and the residual 
factor Xa activity is inversely proportional to the 
heparin concentration. It is assumed that the patient 
has a normal concentration of antithrombin III. 
The test is performed by adding a known amount of 
factor Xa and antithrombin to the plasma of the 
patient. If heparin or LMWH is present in the patient 
plasma, it will bind to antithrombin and inhibit factor 
Xa. The amount of residual factor Xa is inversely 
proportional to the amount of heparin in the plasma. 
The amount of residual factor Xa is detected by 
adding a chromogenic substrate that resembles the 
natural substrate of factor Xa. Factor Xa cleaves the 
chromogenic substrate, releasing a coloured 
c o m p o u n d  t h a t  c a n  b e  d e t e c t e d  b y  a  
spectrophotometer. Results are reported as 
anticoagulant concentration in anti-factor Xa 
units/ml, such that high anti-factor Xa values indicate 
high levels of anticoagulation. Deficiencies of 
antithrombin in the patient do not affect the assay, 
because excess antithrombin is provided in the 
reaction.
Specimen is collected in sodium citrate bottle (blue 
top) about four hours after subcutaneous injection of 
LMWH, otherwise, falsely low values may occur. 
Blood sample should be delivered to the processing 
bench immediately or else falsely low values may 
occur (because platelets release platelet factor 4 (PF4) 
which can neutralise heparin or LMWH). For the 
same reason, plasma must be separated from cells as 
soon as possible, ideally within one hour of specimen 
collection. Plasma can be stored for two hours at room 
temperature or on ice or can be frozen.
Laboratory is specifically notified as to which drug 
should be measured (heparin, LMWH). Limitations 
of this test include cost issues and less ready 
availability than the PTT for heparin monitoring.
Patients not on anticoagulants: 0 unit/ml.
Therapeutic range for anti factor Xa for a DVT patient 
differs according to the type of preparation used: 
Heparin 0.3-0.7 units/ml
LMWH: 0.4-1.1 units/ml for twice daily 
subcutaneous dosing.  For once dai ly 
subcutaneous LMWH dosing, the therapeutic 
range is less certain but is approximately 1-2 
units/ml.
Target range for deep vein thrombosis (DVT) 
prophylaxis (prevention): There is no defined 
target range for prophylaxis of deep vein 
thrombosis (DVT) because such anticoagulation 
is not usually monitored. When anti-Xa levels 
have been measured, mean values are usually 
<0.45 units/ml.
Therapeutic range : UFH : 0.3-0.7 U/L
LMWH: 0.5-1.0 U/L
Prophylactic range: UFH : 0.1-0.29 U/L
LMWH: 0.20-0.49 U/L
Specimen drawn at incorrect time (collection 
times are four hours after injection of LMWH, 
six hours after injection of danaparoid)
Specimen transportation time longer than two 
hours.
Patient receiving prophylactic dose, therefore, 
therapeutic range is not applicable and anti-Xa 
level is actually appropriate for dose
Renal failure (with LMWH or danaparoid) 
because of decreased renal clearance.
Heparin contamination, if specimen was drawn 
from an IV heparinized line.
Reference Range for Anti-factor Xa
Causes of Sub Therapeutic Antifactor Xa Level
Causes of Supra Therapeutic Antifactor Xa Level
!
!
!
!
!
!
!
!
11
Labrad May 2007 Volume 32, Issue 2
Automated Reticulocyte Count
Afsheen Farzand Ali, 
Assistant Technologist, Haematology
Reticulocyte count is an index of erythropoietic 
activity of bone marrow. Manual counting through 
supra vital stain is the most common procedure of 
reticulocyte counting however it is fraught with 20-25 
per cent interobserver variation. Introduction of 
automated technologies have greatly increased the 
accuracy and precision of reticulocyte count with the 
coefficient of variation (CV) of 3-12.3 per cent.
The automated technologies are based on the 
principle of flowcytometry and determine the 
reticulocyte count after staining with fluorescent 
(thiazole orange, amamine-o, cyanene) or non 
fluorescent (oxazin 750, new-methylene blue) dyes. 
Briefly, residual RNA in reticulocyte is precipitated 
by the dye while haemoglobin from erythrocyte is 
cleared by acidic reagent leaving stained RNA. In 
each sample, 32,000 red cells are counted and assayed 
by volume conductivity and light scatter (VCS). The 
instrument separates reticulocytes from red and white 
blood cells as well as platelets. In addition, the 
immature reticulocyte fraction (IRF) can also be 
measured by automated instruments depending on the 
intensity of RNA content, whereby mature forms 
show less staining.  IRF may be important from 
diagnostic point of view reflecting increased 
erythropoietic stimulation e.g. regeneration of 
erythropoietic activity in patients receiving bone 
marrow or stem cell transplantation.
Although the reagents used for automated 
reticulocyte counts seem expensive however when 
we consider the cost of labour in manual counting, the 
automated reticulocyte counting appears cost 
effective. 
The automated counting is less laborious, more 
precise and accurate but it has certain limitations as 
howell jolly bodies, red cell fragments, nucleated red 
cells, siderotic inclusions; debris, large platelets and 
platelets clumps are potential sources of error for 
automated reticulocyte counting. Hb-H samples can 
also give erroneously low or high results depending 
on incubation time in the instruments which use new 
methylene blue dye. 
Automated reticulocyte count like the one in manual 
count is useful in differentiating anaemia caused by 
marrow failure or haemolysis. Because of greater 
precision, the automated reticulocyte count can help 
in monitoring erythropoietin response in chronic 
renal failure and marrow recovery in aplastic anaemia 
or malignant disease after therapy.  The immature 
reticulocyte fraction is another tool of automation 
with clinical significance. This may be normal in 
conditions like iron deficiency and anaemia of 
chronic disease, where reticulocyte response is poor. 
In contrast, in conditions like aplastic anaemia, acute 
myeloid leukaemia and myelodysplastic syndrome, 
the IRF may be increased in spite of low or normal 
reticulocyte count. Immature reticulocyte counts 
have also been found to predict the optimal time for 
stem cell harvesting in peripheral blood.
1. J.I. Davies,M.S. Smyth,J.H.J Martin. Automated 
reticulocyte counting: Evaluation of coulter 
STKS haematology analyzer reiculocyte  funtion. 
Clin.Haem.1997;19, 89-92.
2. Carol Briggs, Donna Grant,Samuel J.Machin. 
Comparision of automated reticulocyte counts 
and immature reticulocyte fraction measurements 
obtained with the ABX Pentra 120 retic blood 
analyzer and the Sysmax XE-2100 automated 
hematology analyzer. Laboratory Hematology. 
2001 1;7:75-80.
3. Rudiger Siekmeier, Alexa Bierlich and Werner 
Jarob. Determination of reticulocytes. Three 
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38(3): 245-249.
References
Figure1:
Reticulocyte count as stained by new methylene blue
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2nd Biennial Conference for Chemical 
Pathologist: 
PSCP Collaborate with AKU  
Reported by Dr Imran Siddiqui
Associate Professor, Chemical Pathology
The two-day 2nd Biennial 
Conference of Pakistan 
S o c i e t y  o f  C h e m i c a l  
Pathologists (PSCP) opened 
at Liaquat National Hospital 
and PNS Shifa on  March 9 
and at Aga Khan University 
(AKU) on March 10, 2007. 
Organised by PSCP and 
hos ted  by  AKU.  The  
Conference also included 
two workshops. Invited 
speakers from Singapore, 
Islamabad and Lahore as well as from Aga Khan 
University Hospital (AKUH), presented their papers 
on this sub-specialty and findings from latest 
research. The Conference's inaugural session was 
well attended by professionals from all over Pakistan, 
and was opened by Lt. Gen (Retd) S. Azhar Ahmed, 
Vice Chancellor  Baqai University, Karachi, who also 
Triple Screen Test
How is the Triple Screen Test Performed?
When is the Triple Screen Test Performed?
What Does the Triple Screen Test Look For?
Dr Beena Umar
Resident, Histopathology
Triple test is a maternal blood screening test that looks 
for three specific substances; AFP, hCG, and Estriol.  
AFP: alpha-fetoprotein is a protein that is produced 
by the foetus.
hCG : human chorionic gonadotropin is a hormone 
produced within the placenta
Estriol: estriol is an estrogen produced by both the 
foetus and the placenta
It is a non-invasive procedure done through a blood 
test with little to no known risk to the mother or 
developing baby.
The triple screen test involves drawing blood from the 
mother which takes few minutes. The blood sample is 
then sent to the laboratory for testing and the results 
come in few days.
The triple screen test is performed between the 15th 
and 20th week of pregnancy although results obtained 
in the 16th -18th week are said to be the most accurate. 
All pregnant women should be offered for triple 
screen, but it is recommended for women who:
have a family history of birth defects; 
are 35 years or older;
used possible harmful medications or drugs 
during pregnancy; 
have diabetes and use insulin; 
had a viral infection during pregnancy; 
have been exposed to high levels of radiation. 
The triple screen is measuring high and low levels of 
AFP and abnormal levels of hCG and estriol. The 
results are combined with the mother's age, weight, 
ethnicity and gestation of pregnancy in order to assess 
probabilities of potential genetic disorders.
High levels of AFP may suggest that the developing 
baby has a neural tube defect such as spina bifida or 
anencephaly. However, the most common reason for 
!
!
!
!
!
!
elevated AFP levels is inaccurate dating of the 
pregnancy.
Low levels of AFP and abnormal levels of hCG and 
estriol may indicate that the developing baby has 
Trisomy 21(Down's syndrome), Trisomy 18 
(Edwards Syndrome) or another type of chromosome 
abnormality. 
The triple test signifies that the mother may be at a 
possible risk of carrying a baby with a genetic 
disorder. It is known to have a high percentage of false 
positive results. Abnormal test results warrant 
additional testing for making a diagnosis like a high 
resolution ultrasound and amniocentesis for 
determining karyotype. If the testing still maintains 
abnormal results, a more invasive procedure like 
amniocentesis may be performed.
What Do the Triple Test Results Mean?
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Chief Guest
Lt. Gen (Retd,)
S. Azhar Ahmed
inaugurated a concurrent 'Scientific Poster 
Exhibition' and a display of pathology-related 
equipment exhibition.
Following a recitation from 
the  Quran ,  Dr  Imran  
S i d d i q u i ,  C h a i r m a n  
Organising Committee, 
welcomed the guests and 
provided an overview of the 
Conference .  Br igadier  
Farooq A. Khan, Deputy 
Commandant, Armed Forces 
Institute of Pathology and 
President PSCP recognised 
the efforts of PSCP and its 
contribution to promote 
education through such 
conferences, especially 
t h a n k i n g  t h e  i n v i t e d  
international and National 
speakers. The chief guest Lt. 
Gen (Retd) S. Azhar Ahmed, 
referred in his speech to the 
importance of linkages in 
healthcare, and highlighted 
the significance of the 
technological innovations. 
The key features of this Conference were two 
workshops namely Recent advancements in chemical 
pathology and role of PCR in chemical pathology. 
Seminar on infertility, plenary lecture and scientific 
session including poster presentations. Joint efforts 
from chemical pathologists of Ziauddin University, 
Liaquat National Hospital and PNS Shifa resulted in 
the success of this scientific meeting. Section of 
Chemical Pathology and Conference Secretariat of 
Aga Khan University led the proceedings. The 
contribution and support of Dean Medical College, 
Aga Khan University, Dr Mohammad Khurshid was 
immense.
The conference was designed to provide an 
opportunity to chemical pathologists, technicians and 
other members of Pakistan's medical community to 
expand and build upon their knowledge and 
understanding of the dynamic field, presently 
undergoing very rapid change with new technology. 
Available facilities in Pakistan are fast increasing and 
the organisers saw the necessity of expanding the pool 
of appropriately-educated chemical pathologists. It is 
important that not only chemical pathologists but all 
healthcare providers keep abreast of the latest trends 
and technologies. This conference provided a relevant 
and quality educational opportunity to the chemical 
pathologists of Pakistan and continued the AKU 
tradition of leadership and excellence in medical 
education. This conference also received coverage in 
the leading newspapers of Karachi.
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Chief Guest Lt. Gen (Retd,), S. Azhar Ahmed
Chancellor Baqai University Inaugurating the Scientific Exhibition  
Dr Imran Siddiqui,
Chair Organizing Committee
Brig Farooq Ahmed Khan,
President PSCP 
Addressing on Occasion 
Dr Shirnen Mansoor, Medical Office AKHU Receive Best Poster
Presentation Award
human factor-notwithstanding
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